Foreign-Exchange Risk Associated With Lactoferrin Imports
First written in FY2018. 14 of 15 entries say "Restated". Latest entry: FY2024-Q2.
The whole theme swung hardest in 2022: 33 of 59 companies on the "Worse" side.
34 other companies' latest entry also says "Restated".
- FY2024-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is stated as having no material changes. - FY2024-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is stated as having no material changes. - FY2023RestatedAnnual report
「The Company seeks to mitigate foreign exchange risk through derivative transactions such as forward exchange contracts, but movements in the foreign exchange market may affect the performance of the business.」
The foreign exchange risk associated with lactoferrin imports and mitigation through forward exchange contracts continue to be disclosed. - FY2023-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is stated as having no material changes. - FY2023-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is stated as having no material changes. - FY2022-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is stated as having no material changes. - FY2021-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is stated as having no material changes. - FY2021-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is stated as having no material changes. - FY2020RestatedAnnual report
「The Company seeks to mitigate foreign exchange risk through derivative transactions such as forward exchange contracts, but movements in the foreign exchange market may affect the performance of the business.」
The foreign exchange risk associated with lactoferrin imports and mitigation through forward exchange contracts continue to be disclosed. - FY2020-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is stated as having no material changes. - FY2020-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is stated as having no material changes. - FY2019-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is disclosed collectively as having no material changes. - FY2019-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is disclosed collectively as having no material changes. - FY2019-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The foreign exchange risk associated with lactoferrin imports is disclosed collectively as having no material changes. - FY2018First statedAnnual report
「The Company seeks to mitigate foreign exchange risk through derivative transactions such as forward exchange contracts and currency options, but movements in the foreign exchange market may affect the performance of the business.」
The Company recognizes the foreign exchange risk associated with lactoferrin purchased from foreign companies in foreign currencies and discloses mitigation measures using forward exchange contracts and currency options.